Pulmonary Physiology |

The Prevalence of Osteopenia and Osteoporosis in Patients With Bronchiectasis FREE TO VIEW

Nathan Diehl; Whitlock Joseph; Margaret Johnson
Author and Funding Information

Mayo Clinic Florida, Jacksonville, FL

Chest. 2014;146(4_MeetingAbstracts):719A. doi:10.1378/chest.1993701
Text Size: A A A
Published online


SESSION TITLE: Cystic Fibrosis/Bronchiectasis Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Define the prevalence of osteopenia and osteoporosis in patients with bronchiectasis

METHODS: We conducted a retrospective chart review of all patients with physician diagnosed bronchiectasis evaluated at Mayo Clinic Florida between 1/1/11 and 6/3/13.

RESULTS: We identified 113 patients with physician diagnosed bronchiectasis and confirmatory findings on computed tomography scan. The cohort was overwhelmingly female (90%) with a mean age 72 +/- 10.6 and BMI of 25.1 +/- 7.05. Most were never (53%) or past smokers (36%) and airflow obstruction was present in 58%. 57 patients (50.44%) and 45 patients (39.82%) were using proton pump inhibitors (PPI) and inhaled corticosteroids(ICS), respectively.79/113 (70%) had a documented history of osteopenia or osteoporosis. The presence or absence of osteoporosis or osteopenia was unknown in 25/113 (22%). Bone mineral density (BMD) testing was performed during the study period in 70/113 (62%) of subjects; 19/70 (27%) had osteoporosis, 41/70 (39%) had osteopenia, and 10/70(14%) had normal BMD. Diminished bone mass was present in 22/27 (80%) patients < age 70, with 7/27 (26%) having osteoporosis. Many patients with BMD T-score values >-2.5 for lumbar spine (43%), left (57%) and right femoral neck (40%), and left (67%) and right hip (50%) were current or former smokers. 47% and 32% of osteopenic or osteoporotic patients with bronchiectasis utilizing PPI and ICS, respectively.

CONCLUSIONS: Diminished bone density is very common in patients with bronchiectasis. Although the prevalence of both bronchiectasis and diminished bone density increase with advancing age and female gender, these data suggest a greater prevalence than expected based on demographic risks alone (Looker, AC, NCHS April 2012). Medication use that may predispose to diminshed bone density is not uncommonly prescribed in patients with bronchiectasis.

CLINICAL IMPLICATIONS: Provider awareness of the potentially increased prevalence of diminished bone density in patients with bronchiectasis may improve patient care by prompting appropriate screening for and treatment of osteoporosis and osteopenia and minimization of medications that may worsen the condition .​

DISCLOSURE: The following authors have nothing to disclose: Nathan Diehl, Whitlock Joseph, Margaret Johnson

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Osteoporosis: an ignored complication of CVID. Pediatr Allergy Immunol 2011;22(7):676-83.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543